Copy Link Print Information

Monalizumab

(Synonyms: IPH2201)
5 Cited Publications
고객리뷰

Based on 5 publication(s) in Google Scholar

Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

  • 보관:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Experimental Validation Results for Monalizumab
  • Experimental Validation Results for Monalizumab
  • Experimental Validation Results for Monalizumab
  • Experimental Validation Results for Monalizumab
  • Experimental Validation Results for Monalizumab
  • Experimental Validation Results for Monalizumab
  • Experimental Validation Results for Monalizumab
  • Experimental Validation Results for Monalizumab
  • Monalizumab Chemical Structure
    Monalizumab Chemical Structure
CAS No.: 1228763-95-8
사이즈
가격
재고
수량
Amount: USD 0.00
Please select quantity
or
or

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
주변의 대리점 찾기 Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • 순도&문서
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Monalizumab

More
Customer Validation & Images
Flow CytometryIn Vivo Efficacy StudyELISA
  • Flow Cytometry
  • In Vivo Efficacy Study
  • ELISA
  • Flow Cytometry
  • Flow Cytometry
  • Flow Cytometry

All Checkpoint Kinase (Chk) Isoforms

More
Keywords
100 mg

견적 받기 해외재고보유

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress 로그인
Register
Sign in to MedChemExpress
회원가입

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 1/16

    Human IgG4 kappa

  • 1/16

    Immobilized NKG2A-CD94 Heterodimer Protein, Human (HEK293, His-Flag, HY-P70713) can bind Monalizumab. The EC50 for this effect is 4.83 ng/mL.

  • 1/16

    Monalizumab purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Nov 28;16(1):865. [Abstract]

    Customer Validation
     Healthy donor PBMCs were co-cultured with SKO-007 (J3) target cells, either untreated or treated with the indicated inhibitors for 48 h. NK cell degranulation assay was conducted at an Effector/Target (E/T) ratio of 2.5:1 in complete medium at 37 °C and 5% CO2 for 2 h. To assess the role of the NKG2A or KIR receptors, NK cells pretreated with blocking mAbs for NKG2A (Monalizumab,15 min) or IgG control were incubated with Pol I inhibitor-treated target cells.

  • 1/16

    Monalizumab purchased from MedChemExpress. Usage Cited in: Carcinogenesis. 2025 Oct 22:bgaf069. [Abstract]

    Customer Validation
     Monalizumab (MNZ) (300 μg/100 μL/mouse; i.p.; once a week for five consecutive weeks). Body weights and tumor volumes were measured twice a week from the seventh day after injection of cancer cells.

  • 1/16

    Monalizumab purchased from MedChemExpress. Usage Cited in: Carcinogenesis. 2025 Oct 22:bgaf069. [Abstract]

    Customer Validation
     Plasma perforin concentrations were determined by ELISA. The results showed that Monalizumab (MNZ) (300 μg/100 μL/mouse; i.p.; once a week for five consecutive weeks) treatment significantly increased perforin levels, which were lower in RT-R-MDA-MB-231-injected mice than in MDA-MB-231-injected mice.

  • 1/16

    Monalizumab purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Jul 1; 12(7): e009410. [Abstract]

    Customer Validation
     Degranulation of NKG2A+ KIR− NK cells after 4 hours of co-culture with untreated or 12 hours IFNγ-pretreated WT or HLA-E KO A375 cells in the presence of 5 µg/mL IgG1 or Monalizumab (mona) mAb (n=6).

  • 1/16

    Monalizumab purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Jul 1; 12(7): e009410. [Abstract]

    Customer Validation
     Reduction in B2M KO cell population after 24 hours of co-culture of NK cells with mixed WT:B2M KO cells (1:1) at different E:T ratios in the presence of 5 µg/mL of indicated mAbs (Monalizumab (mona), etc.).

  • 1/16

    Monalizumab purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 Jan 8;42(1):135-156.e17. [Abstract]

    Customer Validation
     Flow cytometry panels demonstrating the expression level of NKG2A⁺, PD-1⁺Tim-3⁺, Granzyme B⁺ and IFN-γ⁺ in CD8⁺ tumor infiltrating T cells co-cultured with HLA-E⁺ tumor infiltrating B cells, either treated without Monalizumab (upper panel) or with Monalizumab (100 mg/mL; 20 h) (bottom panel).

  • Monalizumab Chemical Structure
    1/16
  • Monalizumab
  • Immobilized NKG2A-CD94 Heterodimer Protein, Human (HEK293, His-Flag, HY-P70713) can bind Monalizumab. The EC50 for this effect is 4.83 ng/mL.